Clinical trial NCT00136032 - References

Growth Hormone Deficiency — Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Citation(s)

•   Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A
  Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996 Dec 1;125(11):883-90.
•   Bengtsson BA, Edén S, Lönn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström L, Isaksson OG
  Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993 Feb;76(2):309-17.
•   Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W, Sharp P, Johnston DG
  The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab. 1995 Feb;80(2):356-63.
•   Binnerts A, Deurenberg P, Swart GR, Wilson JH, Lamberts SW
  Body composition in growth hormone-deficient adults. Am J Clin Nutr. 1992 May;55(5):918-23.
•   Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S, Labrousse F, Pastene J, Sassolas A, Roux Y, Berthezène F
  Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab. 1999 Apr;84(4):1329-33.
•   Bülow B, Hagmar L, Eskilsson J, Erfurth EM
  Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab. 2000 Feb;85(2):574-84.
•   Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, Fazio S, Di Rella F, Biondi B, Lombardi G, Saccà L
  Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab. 1997 May;82(5):1378-81.
•   Colao A, di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
  Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab. 2001 May;86(5):1874-81.
•   Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D
  The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults. J Clin Endocrinol Metab. 1998 Jan;83(1):107-16.
•   Cuneo RC, Salomon F, McGauley GA, Sönksen PH
  The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992 Nov;37(5):387-97. Review.
•   De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA
  Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab. 1992 Sep;75(3):833-7.
•   Evans LM, Davies JS, Goodfellow J, Rees JA, Scanlon MF
  Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1999 Apr;50(4):457-64.
•   Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA
  Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Dec;45(6):769-73.
•   Fowelin J, Attvall S, Lager I, Bengtsson BA
  Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism. 1993 Nov;42(11):1443-7.
•   Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ
  Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation. 1997 Nov 4;96(9):2914-9.
•   Geffner M
  Effects of growth hormone and insulin-like growth factor I on T- and B-lymphocytes and immune function. Acta Paediatr Suppl. 1997 Nov;423:76-9. Review.
•   Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT
  Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab. 1997 Oct;82(10):3285-92.
•   Inoue T, Saito H, Fukushima R, Inaba T, Lin MT, Fukatsu K, Muto T
  Growth hormone and insulinlike growth factor I enhance host defense in a murine sepsis model. Arch Surg. 1995 Oct;130(10):1115-22.
•   Jarrar D, Wolf SE, Jeschke MG, Ramirez RJ, DebRoy M, Ogle CK, Papaconstaninou J, Herndon DN
  Growth hormone attenuates the acute-phase response to thermal injury. Arch Surg. 1997 Nov;132(11):1171-5; discussion 1175-6.
•   Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA
  Growth hormone-deficient adults are insulin-resistant. Metabolism. 1995 Sep;44(9):1126-9.
•   Johansson JO, Landin K, Tengborn L, Rosén T, Bengtsson BA
  High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb. 1994 Mar;14(3):434-7.
•   Jørgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS
  Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989 Jun 3;1(8649):1221-5.
•   Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB
  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.
•   Kuller LH, Tracy RP, Shaten J, Meilahn EN
  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996 Sep 15;144(6):537-47.
•   Leong KS, Mann P, Wallymahmed M, MacFarlane IA, Wilding JP
  Abnormal heart rate variability in adults with growth hormone deficiency. J Clin Endocrinol Metab. 2000 Feb;85(2):628-33.
•   Libby P, Ridker PM
  Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999 Sep 14;100(11):1148-50.
•   Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G
  Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf). 1998 Feb;48(2):137-43.
•   Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG
  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 1992 Nov 14;340(8829):1188-92.
•   Nolte W, Rädisch C, Armstrong VW, Hüfner M, von zur Mühlen A
  The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. Eur J Endocrinol. 1997 Nov;137(5):459-66.
•   Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN
  Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab. 1999 Feb;84(2):453-7.
•   Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH
  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.
•   Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH
  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973-9. Erratum in: N Engl J Med 1997 Jul 31;337(5):356.
•   Ridker PM, Glynn RJ, Hennekens CH
  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998 May 26;97(20):2007-11.
•   Ridker PM
  Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999 Jun 1;130(11):933-7. Review.
•   Rosén T, Bengtsson BA
  Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990 Aug 4;336(8710):285-8.
•   Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson BA
  Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993 Sep;129(3):195-200.
•   Salomon F, Cuneo RC, Hesp R, Sönksen PH
  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797-803.
•   Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A
  Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000 Jul 18;133(2):111-22.
•   Sesmilo G, Miller KK, Hayden D, Klibanski A
  Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001 Dec;86(12):5774-81.
•   Shahi M, Beshyah SA, Hackett D, Sharp PS, Johnston DG, Foale RA
  Myocardial dysfunction in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality. Br Heart J. 1992 Jan;67(1):92-6.
•   Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM
  Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001 Feb 10;357(9254):425-31.
•   Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH
  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1121-7.
•   Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J
  The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab. 1995 Jan;80(1):153-9.
•   Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR
  Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf). 1992 Jan;36(1):45-52.
•   Wüster C, Slenczka E, Ziegler R
  [Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?]. Klin Wochenschr. 1991 Oct 18;69(16):769-73. German.

Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency

Details for clinical trial NCT00136032